Active, Not Recruiting
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859
- Conditions
- Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +54 more
- Locations
-
- Name of Institution: Orlando Health Cancer Institute Orlando, Florida, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Washington University - School of Medicine St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center New York, United States